Stockscreener 앱 받기
0.1297
2.92%
-0.0039
시간 외 거래:
.13
0.0003
+0.23%
전일 마감가:
$0.1336
열려 있는:
$0.1343
하루 거래량:
1.47M
Relative Volume:
0.28
시가총액:
$3.71M
수익:
-
순이익/손실:
$-8.74M
주가수익비율:
-0.0633
EPS:
-2.05
순현금흐름:
$-8.25M
1주 성능:
-2.70%
1개월 성능:
-24.33%
6개월 성능:
-97.33%
1년 성능:
-99.69%
1일 변동 폭
$0.1231
$0.1343
1주일 범위
$0.1231
$0.1398
52주 변동 폭
$0.1231
$62.60
Glucotrack Inc Stock (GCTK) Company Profile
명칭
Glucotrack Inc
전화
972 (8) 675-7878
주소
301 RT 17 NORTH, RUTHERFORD
GCTK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GCTK
Glucotrack Inc
|
0.1297 | 3.82M | 0 | -8.74M | -8.25M | -2.05 |
|
ISRG
Intuitive Surgical Inc
|
552.34 | 193.38B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
172.59 | 49.12B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
85.94 | 42.79B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
244.79 | 35.61B | 5.02B | 1.31B | 1.56B | 8.91 |
|
BAX
Baxter International Inc
|
30.50 | 15.46B | 11.89B | -560.00M | 191.00M | -1.10 |
Glucotrack Inc 주식(GCTK)의 최신 뉴스
GCTK stock plunges to 52-week low, hits $0.13 - Investing.com Australia
GCTK stock plunges to 52-week low, hits $0.13 By Investing.com - Investing.com UK
Upcoming Benzinga Webinar With Glucotrack To Discuss The Potential Of Its Innovative CBGM Technology To Transform Diabetes Care And Patient Lives - FinancialContent
Glucotrack appoints new board member with diabetes tech expertise By Investing.com - Investing.com South Africa
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD - The Manila Times
GCTKGlucotrack Latest Stock News & Market Updates - Stock Titan
GlucoTrack (NASDAQ:GCTK) Trading Down 0.2% – Time to Sell? - Defense World
GlucoTrack Approves Key Proposals at Annual Meeting - TipRanks
GCTK stock plunges to 52-week low, touches $0.13 - Investing.com Australia
GCTK stock plunges to 52-week low, touches $0.13 By Investing.com - Investing.com Nigeria
GlucoTrack Establishes Patient Advisory Board for CBGM - TipRanks
Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development - The Manila Times
Glucotrack, Inc. Forms Patient Advisory Board to Enhance Development of Continuous Blood Glucose Monitor - Nasdaq
Groundbreaking 3-Year Implantable Glucose Monitor Gets Patient-Led Development at Glucotrack - Stock Titan
Glucotrack Reports Q1 2025 Financial Results and Progress - TipRanks
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Innovative Continuous Blood Glucose Monitor Shows Promise in First Human Trial - citybuzz -
GlucoTrack Reports Q1 2025 Financial Results and Progress - TipRanks
Glucotrack, Inc. SEC 10-Q Report - TradingView
Glucotrack, Inc. Advances Continuous Blood Glucose Monitoring Technology with Clinical Study Initiation in Australia by Q3 2025 - Nasdaq
Glucotrack Reports First Quarter 2025 Financial Results And Recent Corporate Highlights - marketscreener.com
Breakthrough: Glucotrack's Implantable Diabetes Monitor Hits Clinical Milestone, FDA Decision Expected Q4 - Stock Titan
Glucotrack gains HREC approval for clinical study of CBGM device - Yahoo Finance
First-In-Human Study In The Bag, Glucotrack Gears Up For Long-Term Trial Of Potentially Groundbreaking Continuous Blood Glucose Monitor For Diabetes Patients - FinancialContent
Certain Options of GlucoTrack, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
Certain Common Stock of GlucoTrack, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
GlucoTrack Gains Approval for Long-Term Clinical Study - TipRanks
Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor - The Manila Times
Geode Capital Management LLC Increases Stock Holdings in GlucoTrack, Inc. (NASDAQ:GCTK) - Defense World
GlucoTrack Inc (GCTK) can make a big difference with a little luck - Sete News
Medtech CEO Shares Lessons From FIH Implantable Glucose Monitor Trial - Clinical Leader
GlucoTrack Releases Investor Presentation on April 29 - TipRanks
GlucoTrack Inc (NASDAQ:GCTK) stock crossing the finish line today - uspostnews.com
Can GlucoTrack Inc Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Now Is The Time To Build A Position In GlucoTrack Inc (NASDAQ:GCTK) - Marketing Sentinel
Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights - ADVFN
It makes sense and dollars to buy GlucoTrack Inc (GCTK) stock - Sete News
Pre-market Movers: OPTN, WINT, AKBA, GCTK... - RTTNews
GlucoTrack Joins EU Bionic Pancreas Initiative - TipRanks
Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas - The Manila Times
Major Breakthrough: Glucotrack Selected for EU's Revolutionary Bionic Pancreas Project - Stock Titan
Glucotrack to bring CBGM to bionic pancreas initiative in Europe - Drug Delivery Business
Investing in GlucoTrack Inc (GCTK) might be an excellent idea, but the stock is currently overvalued/undervalued - uspostnews.com
GCTK stock plunges to 52-week low of $0.15 amid market turmoil By Investing.com - Investing.com South Africa
GCTK stock plunges to 52-week low of $0.15 amid market turmoil - Investing.com India
Glucotrack faces Nasdaq delisting over share price rule - Investing.com Australia
Glucotrack faces Nasdaq delisting over share price rule By Investing.com - Investing.com South Africa
Glucotrack partners with OneTwo Analytics for AI diabetes data analysis By Investing.com - Investing.com South Africa
6 Alternatives to Apple’s Non-Invasive Glucose Monitoring You Can Try Now - The Mac Observer
GlucoTrack Partners with OneTwo Analytics for AI-Driven Insights - TipRanks
Glucotrack partners with OneTwo Analytics for AI diabetes data analysis - Investing.com Australia
Glucotrack Inc (GCTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.66%
1.15%
자본화:
|
볼륨(24시간):